India’s biotechnology sector is undergoing a significant transformation. The country is now increasingly positioning itself as a hub for innovation-driven biotechnology, advanced biomanufacturing, and translational research. The momentum is visible not only in the rapid expansion of biotech startups but also in the emergence of new policy frameworks, biofoundries, and industry-academia collaborations designed to accelerate the journey from laboratory discoveries to market-ready products.

Yet, despite this progress, one of the biggest challenges facing India’s biotech-pharma ecosystem remains the gap between proof-of-concept research and commercialization. Academic laboratories across the country are generating promising innovations in biomaterials, biologics, diagnostics, regenerative medicine, and synthetic biology. However, only a limited number of these technologies successfully progress through pilot-scale validation, regulatory approval,manufacturing scale-up, and market adoption. 

Bridging the “Valley of Death” in Biotech Innovation

This “missing middle”, which is also known as “valley of death” remains the weakest link in  innovation pipeline. The issue is not a lack of scientific talent. India today has a vibrant  biotechnology ecosystem supported by thousands of startups, expanding incubator networks, and  increasing public investment in translational research. According to the India BioEconomy Report  2026, the country’s bioeconomy reached nearly $195 billion in 2025, driven by strong growth in  biopharmaceuticals, precision therapeutics, industrial biotechnology, and deep-tech startups. The  challenge lies in building systems that can reliably convert scientific discoveries into clinically and  commercially deployable products.  

A critical component of this transition is strengthening Technology Transfer Offices (TTOs). In  many Indian institutions, TTOs primarily focus on patent filing and intellectual property  management. While these functions are important, successful translation requires much broader  engagement. Globally, effective technology transfer offices actively evaluate market potential,  identify commercialization pathways, negotiate licensing agreements, and facilitate startup  formation and industrial partnerships. 

Why Technology Transfer Offices Need a Strategic Overhaul

India’s institutions now need to upgrade TTOs as strategic innovation units rather than  administrative support cells. Researchers developing technologies should receive early guidance  on regulatory requirements, manufacturing feasibility, and commercialization strategies. Without  such support, many technologies remain trapped within academic publications and patents.  Another major bottleneck is pilot-scale validation. Laboratory-scale experiments are often  optimized for scientific demonstration rather than manufacturability. Translating biotech products  into real-world applications requires addressing issues such as reproducibility, sterility, packaging,storage stability, and quality control.     

These challenges become particularly important in biomedical products, where regulatory approval depends heavily on consistency and scalability.  Recognizing this gap, recent government initiatives have begun to emphasize translational  infrastructure. Under the BioE3 Policy, India has launched a National Biofoundry Network aimed  at accelerating advanced biomanufacturing and pre-commercial scale validation. The initiative  brings together multiple bio-enabler facilities across the country to support startups, SMEs, and  academic innovators working on technologies ranging from precision therapeutics and mRNA  systems to industrial biotechnology and sustainable biomanufacturing. These facilities could  become transformative for Indian biotech once they evolve into accessible translational platforms  that bridge laboratory research and industrial production. Equally important is the growing role of Contract Development and Manufacturing Organizations  (CDMOs). India’s pharmaceutical sector has already established strong global capabilities in  contract manufacturing, and recent trends indicate increasing interest in high-value biologics,  advanced therapeutics, and complex biopharmaceutical manufacturing. Companies are now  investing heavily in specialized CDMO capabilities for antibody-drug conjugates, cell therapies,  and precision biologics. 

Startup spinouts are also emerging as a critical bridge between academia and industry. Over the  last decade, India has witnessed the rapid growth of biotech entrepreneurship, supported by  organizations such as Biotechnology Industry Research Assistance Council and various incubators  and innovation missions. Increasingly, faculty members and researchers are creating startups to  drive translational development, allowing technologies to move beyond grant-funded academic  research toward product-focused execution.

India now stands at a pivotal moment. The country possesses scientific talent, entrepreneurial  energy, manufacturing expertise, and growing policy support. What is needed next is tighter  integration across the translational pipeline. Technology Transfer Offices must evolve into  commercialization engines. Pilot-scale infrastructure must become widely accessible. CDMO  partnerships should be embedded early into product development. Regulatory literacy must  become part of academic innovation culture. Most importantly, translational research must be  recognized not merely as an extension of science, but as a strategic national capability.  

From Scientific Discovery to Scalable Healthcare Solutions

The future of India’s biotech-pharma ecosystem will not be determined solely by how many  discoveries emerge from laboratories. It will depend on how effectively those discoveries are  transformed into scalable products, accessible technologies, and real-world healthcare solutions.  The journey from lab bench to market is difficult, but it is also where scientific innovation creates  its greatest societal impact. India now has the opportunity to build an ecosystem capable of making  that journey far more efficient, collaborative, and globally competitive.  

About Author: Prof. Devendra Verma is the Head of Department of Biotechnology and Medical Engineering, NIT Rourkela